Feugiat nulla facilisis at vero eros et curt accumsan et iusto odio dignissim qui blandit praesent luptatum zzril.
+ (123) 1800-453-1546
info@example.com

Related Posts

OPHTHALMOLOGICAL INSTITUTE   OPHTALMOLOGICAL RESEARCH FOUNDATION   UNIVERSITY INSTITUTE   FERNÁNDEZ-VEGA FOUNDATION  Do we call you?
Welcome to MedicalPress a Premium Medical Theme
Title Image
You are in:  / Home  /  HOSPITAL PHARMACY AND NEW TREATMENTS  /  CLINICAL RESEARCH UNIT

CLINICAL RESEARCH UNIT

Clinical research is the basic feature that allows medicines to be authorized with the guarantees required by law and ultimately to become part of clinical practice for the benefit of patients. It also allows new forms of use to be researched once the medicines are already commercialized.

In short, clinical research enables the generation of high quality knowledge to develop therapeutic tools that improve those already available, and which contribute to the prevention, relief and cure of diseases and to the improvement of people´s quality of life.

 
RESEARCHER:
Dr. Jesús Merayo Lloves
RECLUTANDO

 

Double masked SYL1001 study in patients with moderate or severe dry eye disease

 

INDICATION: Patients with moderate to severe dry eye
TREATMENT: SYL1001
PROMOTOR: SYLENTIS
 

 

RESEARCHER:
Dr. Álvaro Fernández-Vega Sanz
RECLUTANDO

 


INDICATION: Macular edema secondary to occlusion of the central
TREATMENT: Aflibercept
PROMOTOR: Bayer AG

 

RESEARCHER:
Dr. Álvaro Fernández-Vega Sanz
ACTIVO

 

Phase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC)

INDICATION: Patients with polypoid choroidal vasculopathy
TREATMENT: Aflibercept
PROMOTOR: AIBILI

 

RESEARCHER:
Prof. Luis Fernández-Vega Sanz
RECLUTANDO

 

A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD)

INDICATION: Pacientes con degeneración macular asociada a la edad (DMAE húmeda).
TREATMENT: OPT-302
PROMOTOR: OPTHEA

 

RESEARCHER:
Dr. Álvaro Fernández-Vega Sanz
ACTIVO

 

Treatment of age-related macular degeneration of the neovascular type (DMAEh) over 2 years with a treatment and extension model (T + E) of 2 mg aflibercept injected into the eye.

INDICATION: Patients with Macular Degeneration Associated with the Wet Age
TREATMENT: Aflibercept
PROMOTOR: Bayer AG

 

RESEARCHER:
Dr. Jesús Merayo Lloves
RECLUTANDO

 

"Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye"

INDICATION: Pacientes con ojo seco leve o moderado
TREATMENT: AVX-012
PROMOTOR: Avizorex Pharma

 

RESEARCHER:
Dr. Jesús Merayo Lloves
ACTIVO

 

A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety monitoring three months after treatment in patients with moderate to severe xerophthalmia.

INDICATION: Moderate to severe dry eye
TREATMENT: Ciclosporina
PROMOTOR: Mc2 biotec- Iris Pharma

 

RESEARCHER:
Dr. Jesús Merayo Lloves
FINALIZADO

 

Efficacy and safety of T4020 versus its vehicle in patients with chronic neurotrophic keratitis or corneal ulcer.

INDICATION: Patients with neurotrophic keratitis or neurotrophic corneal ulcer
TREATMENT: Cacicol®
PROMOTOR: Laboratoires THÉA